-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] With the support of favorable policies, the market prospects of the traditional Chinese medicine industry are optimistic about the pharmaceutical companie.
Some data predict that the scale of the traditional Chinese medicine market will exceed one trillion in 2022 and reach 1375 trillion yuan in 2024.In the face of considerable market prospects, more and more pharmaceutical companies are entering the traditional Chinese medicine marke.
For example, recently, Wanbangde said in an investor survey that in the future, the company's pharmaceutical manufacturing sector will focus on the traditional Chinese medicine industry, jointly develop traditional Chinese medicine products, sort out the existing 24 traditional Chinese medicine products and carry out secondary research and development, and will not rule out mergers and acquisition.
Chinese medicine product structur.
On July 25, Wanbonde announced in the evening that it planned to acquire a total of 238 million shares of Hong Kong-listed company Kangchen Pharmaceutical by paying cash, accounting for 250% of its total share capita.
According to the data, Kangchen Pharmaceutical is a modern pharmaceutical company engaged in the research, development, production and sales of proprietary Chinese medicines and medical imaging contrast agent.
On August 9, Dorui Medicine also announced that the company intends to acquire a 40% stake in Bozhou Tianji held by Hubei Tianj.
For the purpose of this acquisition, Dorui Medicine stated that it is conducive to accelerating the improvement of the company's traditional Chinese medicine industry layout and further enhancing the company's profitabilit.
It is understood that Sinopharm Group has been accelerating the layout of the entire Chinese medicine industry chain through restructuring and integration in recent year.
According to the data, from 2013 to 2015, it acquired Yingtian Pharmaceutical, Tongjitang, Tianjiang Pharmaceutical and Yifang Pharmaceutical; in 2021, it strategically reorganized Taiji Grou.
.
In the ten years from 2012 to 2021, the modern Chinese medicine sector of Sinopharm Group operated Benefit has been greatly improve.
The data shows that by the end of 2021, it has realized an asset scale of 5605 billion yuan, an operating income of 3755 billion yuan, a net profit of 069 billion yuan, and a 10-year profit compound growth rate of 67.
Traditional Chinese medicine is a treasure of the Chinese natio.
The industry said that inheriting the traditional Chinese medicine culture is of great significance for promoting the excellent traditional Chinese culture and establishing national cultural confidenc.
It is understood that in recent years, under the promotion of the state, the local distribution of traditional Chinese medicine has also significantly accelerate.
For example, on August 1, the "Regulations on Traditional Chinese Medicine in Shanxi Province" was officially implemente.
Prior to this, the relevant departments of Shanxi Province and Taiyuan City have successively issued the "Implementation Plan for Building a Strong TCM Province" and the "Implementation Plan for Building a Strong City of Traditional Chinese Medicine", making it clear that Taiyuan will implement 10 projects including the construction of key specialties of traditional Chinese medicin.
The special action for the revitalization and development of traditional Chinese medicine has driven the continuous improvement of the service capacity of traditional Chinese medicine in Taiyua.
Shanghai also recently released the "Shanghai National TCM Comprehensive Reform Demonstration Zone Construction Plan", which will focus on exploring and building a new model for the coordinated development of TCM and Western medicine, a highland for international standardization of TCM, and striving to become the source of TCM technological innovatio.
In the context of a series of favorable policies, aging population and consumption upgrade, the Chinese medicine industry has developed rapidly, and more and more pharmaceutical companies have accelerated the deployment of Chinese medicine through acquisitions, mergers, or restructuring and integratio.
The industry said that in the face of sustainable development in the future, traditional Chinese medicine companies also need to focus on innovative research and developmen.
It is reported that this time, Shanghai Western Medical University and TCM colleges have jointly established the Institute of Traditional Chinese Medicine and Western Medicine Convergence Innovation, which takes major clinical problems as the breakthrough point, explores breakthroughs in major key theories, and creates an innovative highland for TCM and Western medicin.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
Some data predict that the scale of the traditional Chinese medicine market will exceed one trillion in 2022 and reach 1375 trillion yuan in 2024.In the face of considerable market prospects, more and more pharmaceutical companies are entering the traditional Chinese medicine marke.
For example, recently, Wanbangde said in an investor survey that in the future, the company's pharmaceutical manufacturing sector will focus on the traditional Chinese medicine industry, jointly develop traditional Chinese medicine products, sort out the existing 24 traditional Chinese medicine products and carry out secondary research and development, and will not rule out mergers and acquisition.
Chinese medicine product structur.
On July 25, Wanbonde announced in the evening that it planned to acquire a total of 238 million shares of Hong Kong-listed company Kangchen Pharmaceutical by paying cash, accounting for 250% of its total share capita.
According to the data, Kangchen Pharmaceutical is a modern pharmaceutical company engaged in the research, development, production and sales of proprietary Chinese medicines and medical imaging contrast agent.
On August 9, Dorui Medicine also announced that the company intends to acquire a 40% stake in Bozhou Tianji held by Hubei Tianj.
For the purpose of this acquisition, Dorui Medicine stated that it is conducive to accelerating the improvement of the company's traditional Chinese medicine industry layout and further enhancing the company's profitabilit.
It is understood that Sinopharm Group has been accelerating the layout of the entire Chinese medicine industry chain through restructuring and integration in recent year.
According to the data, from 2013 to 2015, it acquired Yingtian Pharmaceutical, Tongjitang, Tianjiang Pharmaceutical and Yifang Pharmaceutical; in 2021, it strategically reorganized Taiji Grou.
.
In the ten years from 2012 to 2021, the modern Chinese medicine sector of Sinopharm Group operated Benefit has been greatly improve.
The data shows that by the end of 2021, it has realized an asset scale of 5605 billion yuan, an operating income of 3755 billion yuan, a net profit of 069 billion yuan, and a 10-year profit compound growth rate of 67.
Traditional Chinese medicine is a treasure of the Chinese natio.
The industry said that inheriting the traditional Chinese medicine culture is of great significance for promoting the excellent traditional Chinese culture and establishing national cultural confidenc.
It is understood that in recent years, under the promotion of the state, the local distribution of traditional Chinese medicine has also significantly accelerate.
For example, on August 1, the "Regulations on Traditional Chinese Medicine in Shanxi Province" was officially implemente.
Prior to this, the relevant departments of Shanxi Province and Taiyuan City have successively issued the "Implementation Plan for Building a Strong TCM Province" and the "Implementation Plan for Building a Strong City of Traditional Chinese Medicine", making it clear that Taiyuan will implement 10 projects including the construction of key specialties of traditional Chinese medicin.
The special action for the revitalization and development of traditional Chinese medicine has driven the continuous improvement of the service capacity of traditional Chinese medicine in Taiyua.
Shanghai also recently released the "Shanghai National TCM Comprehensive Reform Demonstration Zone Construction Plan", which will focus on exploring and building a new model for the coordinated development of TCM and Western medicine, a highland for international standardization of TCM, and striving to become the source of TCM technological innovatio.
In the context of a series of favorable policies, aging population and consumption upgrade, the Chinese medicine industry has developed rapidly, and more and more pharmaceutical companies have accelerated the deployment of Chinese medicine through acquisitions, mergers, or restructuring and integratio.
The industry said that in the face of sustainable development in the future, traditional Chinese medicine companies also need to focus on innovative research and developmen.
It is reported that this time, Shanghai Western Medical University and TCM colleges have jointly established the Institute of Traditional Chinese Medicine and Western Medicine Convergence Innovation, which takes major clinical problems as the breakthrough point, explores breakthroughs in major key theories, and creates an innovative highland for TCM and Western medicin.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
